NASDAQ:ICPT - Intercept Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $65.41
  • Forecasted Upside: 79.60 %
  • Number of Analysts: 23
  • Breakdown:
  • 0 Sell Ratings
  • 15 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$36.42
▲ +0.95 (2.68%)
1 month | 3 months | 12 months
Get New Intercept Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICPT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$65.41
▲ +79.60% Upside Potential
This price target is based on 23 analysts offering 12 month price targets for Intercept Pharmaceuticals in the last 3 months. The average price target is $65.41, with a high forecast of $140.00 and a low forecast of $38.00. The average price target represents a 79.60% upside from the last price of $36.42.
Hold
The current consensus among 23 polled investment analysts is to hold stock in Intercept Pharmaceuticals. This rating has held steady since January 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 10 hold ratings
  • 0 sell ratings
6/3/2019
  • 0 strong buy ratings
  • 9 buy ratings
  • 10 hold ratings
  • 0 sell ratings
9/1/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 10 hold ratings
  • 0 sell ratings
11/30/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 10 hold ratings
  • 0 sell ratings
2/28/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 0 sell ratings
5/28/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 15 hold ratings
  • 0 sell ratings
8/26/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 15 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 15 hold ratings
  • 0 sell ratings
11/24/2020

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 15 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2020B. RileyLower Price TargetBuy$97.00 ➝ $74.00High
i
Rating by Mayank Mamtani at B. Riley
11/11/2020Canaccord GenuityBoost Price TargetHold$42.00 ➝ $58.00Medium
i
Rating by Edward Nash at Canaccord Genuity
11/10/2020BMO Capital MarketsLower Price TargetMarket Perform$56.00 ➝ $38.00High
i
Rating by Matthew Luchini at BMO Capital Markets
11/10/2020Royal Bank of CanadaLower Price TargetSector Perform$49.00 ➝ $40.00High
i
Rating by Brian Abrahams at Royal Bank of Canada
11/10/2020Credit Suisse GroupLower Price TargetHold ➝ Neutral$60.00 ➝ $42.00High
i
Rating by Tiago Fauth at Credit Suisse Group AG
11/10/2020Robert W. BairdUpgradeNeutral ➝ Outperform$52.00High
i
Rating by Brian Skorney at Robert W. Baird
11/10/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$60.00High
i
Rating by Steven Seedhouse at Raymond James
11/10/2020SVB LeerinkLower Price TargetMarket Perform$50.00 ➝ $48.00High
i
11/10/2020Chardan CapitalLower Price TargetBuy$105.00 ➝ $58.00High
i
Rating by Michael Morabito at Chardan Capital
8/28/2020WedbushReiterated RatingBuy$140.00Medium
i
Rating by Liana Moussatos at Wedbush
8/12/2020Canaccord GenuityReiterated RatingHold$58.00Low
i
Rating by Edward Nash at Canaccord Genuity
8/11/2020Royal Bank of CanadaReiterated RatingHold$57.00Low
i
Rating by Brian Abrahams at Royal Bank of Canada
8/11/2020OppenheimerReiterated RatingHold$54.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/11/2020Chardan CapitalReiterated RatingBuy$105.00Medium
i
Rating by Michael Morabito at Chardan Capital
8/10/2020Needham & Company LLCInitiated CoverageBuy$100.00Medium
i
Rating by Alan Carr at Needham & Company LLC
8/10/2020B. RileyReiterated RatingBuy$97.00Medium
i
Rating by Mayank Mamtani at B. Riley
8/10/2020Stifel NicolausBoost Price TargetHold$51.00 ➝ $56.00High
i
7/30/2020Piper SandlerInitiated CoverageOverweight$82.00Medium
i
7/21/2020JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
i
6/30/2020Chardan CapitalReiterated RatingBuy$105.00Low
i
Rating by Michael Morabito at Chardan Capital
6/30/2020CitigroupUpgradeNeutral ➝ Buy$110.00 ➝ $67.00High
i
Rating by Joel Beatty at Citigroup Inc.
6/30/2020SVB LeerinkLower Price TargetMarket Perform$89.00 ➝ $50.00Low
i
Rating by Thomas Smith at SVB Leerink LLC
6/30/2020Needham & Company LLCLower Price TargetBuy$150.00 ➝ $100.00Low
i
Rating by Alan Carr at Needham & Company LLC
6/30/2020UBS GroupDowngradeBuy ➝ Neutral$135.00 ➝ $57.00Medium
i
6/30/2020Robert W. BairdDowngradeOutperform ➝ Neutral$52.00Medium
i
Rating by Brian Skorney at Robert W. Baird
6/30/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$57.00Medium
i
Rating by Alethia Young at Cantor Fitzgerald
6/29/2020B. RileyReiterated RatingBuy$97.00Medium
i
Rating by Mayank Mamtani at B. Riley
6/29/2020WedbushReiterated RatingBuy$140.00Medium
i
Rating by Liana Moussatos at Wedbush
6/29/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$137.00 ➝ $59.00Medium
i
Rating by Tiago Fauth at Credit Suisse Group AG
6/29/2020CowenDowngradeOutperform ➝ Market Perform$149.00 ➝ $47.00Medium
i
6/29/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
6/29/2020Stifel NicolausLower Price TargetHold$100.00 ➝ $51.00High
i
6/29/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$150.00 ➝ $60.00High
i
6/29/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$107.00 ➝ $52.00High
i
Rating by Matthew Luchini at BMO Capital Markets
6/29/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$117.00 ➝ $55.00Medium
i
6/29/2020Canaccord GenuityDowngradeBuy ➝ Hold$58.00High
i
6/29/2020OppenheimerDowngradeOutperform ➝ Market Perform$124.00 ➝ $46.00High
i
6/29/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$146.00 ➝ $46.00High
i
6/25/2020HC WainwrightInitiated CoverageNeutral$92.00Medium
i
Rating by E. Arce at HC Wainwright
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$107.00Low
i
5/22/2020Robert W. BairdReiterated RatingBuy$227.00High
i
Rating by Brian Skorney at Robert W. Baird
5/22/2020B. RileyReiterated RatingBuy$158.00N/A
i
Rating by Mayank Mamtani at B. Riley
5/22/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$145.00 ➝ $115.00High
i
5/14/2020WedbushReiterated RatingBuy$257.00Medium
i
Rating by Liana Moussatos at Wedbush
5/13/2020B. RileyReiterated RatingBuy$158.00High
i
Rating by Mayank Mamtani at B. Riley
5/12/2020Chardan CapitalReiterated RatingBuy$145.00High
i
5/12/2020Stifel NicolausLower Price TargetHold$100.00 ➝ $99.00Medium
i
5/12/2020CitigroupDowngradeBuy ➝ Neutral$110.00Medium
i
Rating by Joel Beatty at Citigroup Inc.
5/11/2020Needham & Company LLCReiterated RatingBuy$150.00High
i
4/27/2020WedbushReiterated RatingBuy$257.00High
i
Rating by Liana Moussatos at Wedbush
4/8/2020Royal Bank of CanadaReiterated RatingBuy$117.00High
i
4/2/2020Chardan CapitalInitiated CoverageBuy$145.00Low
i
3/26/2020WedbushReiterated RatingBuy$257.00High
i
Rating by Liana Moussatos at Wedbush
3/26/2020B. RileyReiterated RatingBuy$158.00High
i
Rating by Mayank Mamtani at B. Riley
3/5/2020Bank of AmericaInitiated CoverageNeutral$111.00Low
i
2/27/2020WedbushReiterated RatingBuy$257.00High
i
Rating by Liana Moussatos at Wedbush
2/26/2020Cantor FitzgeraldReiterated RatingBuy$186.00High
i
Rating by Alethia Young at Cantor Fitzgerald
2/26/2020OppenheimerLower Price Target$146.00 ➝ $124.00Low
i
2/26/2020CitigroupUpgradeNeutral ➝ Buy$140.00 ➝ $125.00High
i
Rating by Joel Beatty at Citigroup Inc.
2/20/2020B. RileyReiterated RatingBuy$158.00N/A
i
Rating by Mayank Mamtani at B. Riley
2/10/2020WedbushReiterated RatingBuy$257.00Medium
i
Rating by Liana Moussatos at Wedbush
1/29/2020WedbushReiterated RatingBuy$257.00Low
i
Rating by Liana Moussatos at Wedbush
1/22/2020WedbushReiterated RatingBuy$257.00Medium
i
Rating by Liana Moussatos at Wedbush
1/9/2020B. RileyBoost Price TargetBuy$133.00 ➝ $158.00Low
i
Rating by Mayank Mamtani at B. Riley
1/2/2020SVB LeerinkReiterated RatingUnderperformMedium
i
Rating by T. Smith at SVB Leerink LLC
1/2/2020CitigroupDowngradeBuy ➝ Neutral$85.00 ➝ $140.00High
i
Rating by Joel Beatty at Citigroup Inc.
12/18/2019WedbushReiterated RatingBuy$257.00Low
i
Rating by Liana Moussatos at Wedbush
12/17/2019Robert W. BairdReiterated RatingBuy$227.00Low
i
Rating by Brian Skorney at Robert W. Baird
12/17/2019Needham & Company LLCReiterated RatingBuy$150.00Low
i
12/17/2019Credit Suisse GroupReiterated RatingOutperform$87.00 ➝ $141.00Low
i
12/17/2019Wells Fargo & CompanyReiterated RatingPositive ➝ Overweight$120.00 ➝ $146.00Low
i
12/13/2019B. RileyReiterated RatingBuy$133.00High
i
Rating by Mayank Mamtani at B. Riley
12/2/2019Canaccord GenuityInitiated CoverageBuyMedium
i
11/25/2019Robert W. BairdReiterated RatingBuy$227.00High
i
Rating by Brian Skorney at Robert W. Baird
11/25/2019Stifel NicolausBoost Price Target$86.00 ➝ $102.00High
i
11/5/2019WedbushReiterated RatingBuy$243.00High
i
Rating by Liana Moussatos at Wedbush
11/5/2019Needham & Company LLCReiterated RatingBuy$150.00Low
i
10/21/2019Raymond JamesLower Price TargetStrong-Buy$148.00 ➝ $147.00High
i
Rating by Steven Seedhouse at Raymond James
10/18/2019Jefferies Financial GroupSet Price TargetBuy$125.00High
i
Rating by Michael Yee at Jefferies Financial Group Inc.
10/18/2019Credit Suisse GroupLower Price Target$167.00 ➝ $87.00Low
i
9/30/2019WedbushSet Price TargetBuy$243.00Low
i
Rating by Liana Moussatos at Wedbush
9/6/2019Royal Bank of CanadaSet Price TargetBuy$135.00Medium
i
Rating by Brian Abrahams at Royal Bank of Canada
9/4/2019CitigroupUpgradeNeutral ➝ Buy$106.00 ➝ $85.00Medium
i
8/23/2019Raymond JamesSet Price TargetBuy$148.00N/A
i
Rating by Steven Seedhouse at Raymond James
8/12/2019Stifel NicolausReiterated RatingHold$86.00Low
i
8/8/2019Royal Bank of CanadaReiterated RatingBuy$135.00Medium
i
8/8/2019Cantor FitzgeraldLower Price TargetOverweight$191.00 ➝ $186.00High
i
8/7/2019Raymond JamesSet Price TargetBuy$149.00Medium
i
Rating by Steven Seedhouse at Raymond James
8/6/2019OppenheimerLower Price TargetOutperform$170.00 ➝ $160.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
7/5/2019WedbushSet Price TargetBuy$243.00Low
i
Rating by Liana Moussatos at Wedbush
6/24/2019Stifel NicolausInitiated CoverageHold ➝ Hold$89.00 ➝ $89.00Medium
i
6/6/2019Raymond JamesReiterated RatingBuyLow
i
Rating by Steven Seedhouse at Raymond James
5/13/2019WedbushReiterated RatingOutperform$251.00 ➝ $243.00Medium
i
Rating by Liana Moussatos at Wedbush
5/8/2019CowenReiterated RatingBuy$149.00Medium
i
5/8/2019B. RileyReiterated RatingBuy ➝ Buy$169.00Medium
i
Rating by Mayank Mamtani at B. Riley
5/2/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$90.02Medium
i
4/29/2019OppenheimerLower Price Target$175.00 ➝ $170.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/12/2019B. RileySet Price TargetBuy$169.00High
i
Rating by Mayank Mamtani at B. Riley
4/12/2019WedbushSet Price TargetBuy$251.00High
i
Rating by Liana Moussatos at Wedbush
4/12/2019Wells Fargo & CompanyBoost Price TargetMarket Perform$99.00 ➝ $104.00High
i
3/28/2019UBS GroupBoost Price TargetBuy$139.00Low
i
3/27/2019WedbushReiterated RatingBuy$251.00Low
i
Rating by Liana Moussatos at Wedbush
3/19/2019OppenheimerReiterated RatingBuyLow
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/5/2019WedbushSet Price TargetBuy$251.00Medium
i
Rating by Liana Moussatos at Wedbush
3/1/2019Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$130.00High
i
2/28/2019B. RileyReiterated RatingBuy ➝ Buy$155.00 ➝ $169.00High
i
Rating by Mayank Mamtani at B. Riley
2/28/2019Raymond JamesSet Price TargetStrong-Buy ➝ Buy$184.00 ➝ $187.00High
i
Rating by Steven Seedhouse at Raymond James
2/28/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$170.00 ➝ $191.00High
i
Rating by A. Young at Cantor Fitzgerald
2/21/2019CitigroupBoost Price TargetNeutral ➝ Neutral$106.00 ➝ $140.00High
i
2/20/2019OppenheimerBoost Price TargetOutperform$140.00 ➝ $175.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/20/2019Royal Bank of CanadaBoost Price TargetSector Perform$137.00High
i
2/20/2019JMP SecuritiesBoost Price TargetOutperform ➝ In-Line$175.00 ➝ $200.00High
i
2/19/2019WedbushBoost Price TargetOutperform ➝ Outperform$220.00 ➝ $248.00High
i
Rating by Liana Moussatos at Wedbush
2/19/2019Wells Fargo & CompanyBoost Price TargetMarket Perform$75.00 ➝ $127.00High
i
2/19/2019Cantor FitzgeraldReiterated RatingBuy$170.00High
i
Rating by A. Young at Cantor Fitzgerald
2/15/2019Bank of AmericaReiterated RatingUnderperform$68.00Low
i
2/14/2019Raymond JamesReiterated RatingBuyLow
i
Rating by Steven Seedhouse at Raymond James
2/12/2019Credit Suisse GroupReiterated RatingOutperformHigh
i
2/4/2019Raymond JamesUpgradeOutperform ➝ Strong-Buy$184.00Low
i
1/31/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$167.00High
i
1/30/2019JMP SecuritiesUpgradeMarket Perform ➝ Outperform$75.00 ➝ $175.00High
i
1/28/2019Jefferies Financial GroupBoost Price TargetBuy$150.00Low
i
1/24/2019Needham & Company LLCUpgradeHold ➝ Buy$150.00High
i
Rating by Alan Carr at Needham & Company LLC
1/23/2019UBS GroupInitiated CoverageBuy ➝ Buy$130.00Low
i
1/14/2019LaidlawUpgradeHold ➝ Buy$99.00 ➝ $130.00Low
i
Rating by Francois Brisebois at Laidlaw
12/11/2018B. RileyInitiated CoverageBuy ➝ Buy$155.00 ➝ $155.00High
i
Rating by Mayank Mamtani at B. Riley
12/6/2018Cantor FitzgeraldReiterated RatingBuy$170.00Low
i
Rating by A. Young at Cantor Fitzgerald
11/19/2018CIBCUpgradeMarket Perform ➝ OutperformMedium
i
11/19/2018OppenheimerUpgradeMarket Perform ➝ Outperform$140.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/19/2018UBS GroupUpgradeMarket Perform ➝ OutperformMedium
i
11/6/2018WedbushSet Price TargetBuy$220.00High
i
Rating by Liana Moussatos at Wedbush
10/31/2018OppenheimerSet Price TargetHold$100.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/31/2018Needham & Company LLCReiterated RatingHoldHigh
i
Rating by Alan Carr at Needham & Company LLC
10/8/2018OppenheimerSet Price TargetHold$100.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/2/2018Raymond JamesDowngradeStrong-Buy ➝ Outperform$126.00 ➝ $141.00High
i
Rating by Steven Seedhouse at Raymond James
10/1/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$170.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
9/12/2018Roth CapitalInitiated CoverageBuy ➝ Buy$192.00Low
i
Rating by Y. Rahimi at Roth Capital
8/15/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$244.00High
i
8/12/2018WedbushSet Price TargetBuy$217.00Medium
i
Rating by Liana Moussatos at Wedbush
8/6/2018WedbushBoost Price TargetOutperform ➝ Outperform$203.00 ➝ $217.00High
i
Rating by Liana Moussatos at Wedbush
8/6/2018The Goldman Sachs GroupUpgradeSell ➝ Buy$46.00 ➝ $157.00High
i
8/3/2018WedbushReiterated RatingBuy$217.00 ➝ $203.00Low
i
8/3/2018LaidlawDowngradeBuy ➝ Hold$90.00 ➝ $95.00Medium
i
Rating by Francois Brisebois at Laidlaw
8/3/2018Royal Bank of CanadaReiterated RatingBuy$115.00High
i
8/2/2018Needham & Company LLCReiterated RatingHoldMedium
i
8/2/2018OppenheimerSet Price TargetHold$100.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/2/2018Cantor FitzgeraldSet Price TargetHold$69.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
7/17/2018OppenheimerSet Price TargetHold$100.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
6/28/2018Raymond JamesInitiated CoverageStrong-Buy$122.00High
i
5/18/2018WedbushReiterated RatingBuyMedium
i
5/11/2018WedbushReiterated RatingBuy$203.00Medium
i
5/9/2018CowenReiterated RatingBuy$88.00Low
i
5/8/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/8/2018Cantor FitzgeraldReiterated RatingHold$58.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
4/17/2018WedbushLower Price TargetOutperform ➝ Outperform$203.00 ➝ $256.00Low
i
3/28/2018Needham & Company LLCReiterated RatingHoldMedium
i
3/20/2018OppenheimerReiterated RatingHoldLow
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/9/2018WedbushReiterated RatingOutperform$256.00 ➝ $253.00High
i
2/15/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$152.00 ➝ $155.00High
i
2/15/2018OppenheimerReiterated RatingHoldHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/14/2018Cantor FitzgeraldSet Price TargetHold$58.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/13/2018Wells Fargo & CompanyReiterated RatingMarket Perform$62.00 ➝ $57.00Medium
i
2/12/2018Deutsche Bank AktiengesellschaftInitiated CoverageBuy$103.00Medium
i
Rating by Navin Jacob at Deutsche Bank Aktiengesellschaft
2/7/2018The Goldman Sachs GroupDowngradeNeutral ➝ SellLow
i
1/29/2018OppenheimerReiterated RatingHoldMedium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/25/2018Robert W. BairdReiterated RatingOutperform$332.00 ➝ $253.00Low
i
1/22/2018Credit Suisse GroupSet Price TargetBuy$201.00 ➝ $167.00High
i
1/5/2018WedbushReiterated RatingBuy$253.00Low
i
12/29/2017CitigroupSet Price TargetHold$74.00High
i
Rating by Joel Beatty at Citigroup Inc.
12/22/2017WedbushReiterated RatingBuy$253.00High
i
12/21/2017CitigroupSet Price TargetHold$74.00Low
i
Rating by Joel Beatty at Citigroup Inc.
12/12/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$106.00High
i
11/28/2017SVB LeerinkReiterated RatingHold$60.00Low
i
11/20/2017WedbushReiterated RatingBuy$253.00N/A
i
11/1/2017Needham & Company LLCReiterated RatingHoldN/A
i
11/1/2017CowenReiterated RatingBuy$112.00N/A
i
11/1/2017Cantor FitzgeraldUpgradeUnderweight ➝ Neutral$69.00N/A
i
Rating by Elemer Piros at Cantor Fitzgerald
11/1/2017LaidlawUpgradeHold ➝ Buy$90.00N/A
i
10/24/2017OppenheimerReiterated RatingHoldN/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/13/2017Bank of AmericaLower Price TargetUnderperform$102.00 ➝ $73.00N/A
i
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$79.00N/A
i
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$136.00N/A
i
Rating by V. Bernardino at Seaport Global Securities
10/4/2017Royal Bank of CanadaReiterated RatingOutperform ➝ OutperformHigh
i
10/4/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
i
9/26/2017JMP SecuritiesReiterated RatingOutperform$150.00 ➝ $140.00Medium
i
9/26/2017Credit Suisse GroupReiterated RatingOutperform$201.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
9/26/2017Jefferies Financial GroupReiterated RatingBuy$275.00 ➝ $135.00Low
i
9/26/2017Needham & Company LLCReiterated RatingHoldLow
i
9/26/2017Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$200.00 ➝ $244.00Medium
i
9/23/2017Robert W. BairdReiterated RatingOutperform$332.00Low
i
9/23/2017SVB LeerinkLower Price TargetMarket Perform$120.00 ➝ $66.00Low
i
9/22/2017UBS GroupDowngradeOutperform ➝ Market PerformLow
i
9/22/2017OppenheimerReiterated RatingOutperform ➝ HoldHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/22/2017BMO Capital MarketsReiterated RatingOutperform$221.00 ➝ $160.00High
i
9/22/2017Morgan StanleyReiterated RatingUnderweight$75.00 ➝ $50.00High
i
9/22/2017CowenReiterated RatingBuy$232.00 ➝ $112.00High
i
9/22/2017LaidlawLower Price TargetHold ➝ Hold$118.00 ➝ $90.00High
i
9/22/2017CitigroupDowngradeBuy ➝ Neutral$150.00 ➝ $92.00High
i
9/21/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$265.00 ➝ $95.00High
i
9/20/2017Jefferies Financial GroupReiterated RatingBuy$275.00High
i
9/19/2017CitigroupReiterated RatingBuy ➝ Neutral$150.00Medium
i
9/15/2017WedbushReiterated RatingOurperform$253.00Low
i
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$244.00High
i
9/14/2017OppenheimerReiterated RatingOutperform$200.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/14/2017CowenReiterated RatingOutperform$232.00Medium
i
9/13/2017BMO Capital MarketsReiterated RatingOutperform$221.00High
i
9/13/2017Robert W. BairdReiterated RatingOutperform$332.00High
i
9/13/2017Jefferies Financial GroupReiterated RatingBuy$275.00High
i
9/13/2017Cantor FitzgeraldReiterated RatingUnderweight$69.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
9/13/2017Wells Fargo & CompanyReiterated RatingOutperformHigh
i
8/25/2017WedbushReiterated RatingOutperform$253.00Low
i
8/8/2017Cantor FitzgeraldReiterated RatingUnderweight$60.00 ➝ $69.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
8/1/2017LaidlawReiterated RatingHold$115.00 ➝ $119.00High
i
8/1/2017OppenheimerReiterated RatingOutperform$200.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/1/2017BMO Capital MarketsBoost Price TargetOutperform$218.00 ➝ $221.00Medium
i
7/31/2017WedbushReiterated RatingBuyHigh
i
7/31/2017Cantor FitzgeraldReiterated RatingUnderweight$60.00 ➝ $69.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
7/30/2017Jefferies Financial GroupReiterated RatingBuy$275.00High
i
7/10/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$275.00High
i
6/23/2017WedbushReiterated RatingOutperform$231.00Medium
i
6/13/2017WedbushReiterated RatingOutperform$231.00Medium
i
6/12/2017CowenReiterated RatingBuyMedium
i
6/3/2017Credit Suisse GroupSet Price TargetBuy$201.00Medium
i
Rating by Alethia Young at Credit Suisse Group AG
5/26/2017WedbushReiterated RatingOutperform$231.00High
i
5/15/2017Credit Suisse GroupBoost Price TargetOutperform$198.00 ➝ $201.00N/A
i
5/5/2017Credit Suisse GroupBoost Price TargetOutperform$198.00 ➝ $201.00Low
i
5/5/2017BMO Capital MarketsReiterated RatingOutperform$221.00 ➝ $223.00Low
i
5/5/2017LaidlawUpgradeSell ➝ Hold$115.00Low
i
5/4/2017Cantor FitzgeraldSet Price TargetSell$60.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
5/4/2017OppenheimerSet Price TargetBuy$200.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
4/24/2017CowenReiterated RatingBuy$225.00High
i
4/12/2017OppenheimerReiterated RatingOutperformHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/22/2017OppenheimerReiterated RatingBuyLow
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/17/2017WedbushReiterated RatingOutperform$224.00Low
i
2/28/2017CitigroupSet Price TargetBuy$275.00 ➝ $240.00N/A
i
2/27/2017OppenheimerReiterated RatingOutperform$200.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/24/2017BMO Capital MarketsBoost Price TargetOutperform$198.00 ➝ $221.00N/A
i
2/24/2017SVB LeerinkLower Price TargetMarket Perform$116.00 ➝ $110.00N/A
i
2/24/2017WedbushReiterated RatingOutperform ➝ Positive$224.00N/A
i
2/23/2017Needham & Company LLCReiterated RatingHoldN/A
i
2/23/2017Cantor FitzgeraldSet Price TargetSell$60.00N/A
i
Rating by Elemer Piros at Cantor Fitzgerald
2/16/2017WedbushReiterated RatingOutperform$224.00N/A
i
2/16/2017Robert W. BairdReiterated RatingOutperform$332.00N/A
i
2/16/2017BMO Capital MarketsReiterated RatingOutperform$198.00N/A
i
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00N/A
i
2/13/2017Cantor FitzgeraldReiterated RatingUnderweight$60.00N/A
i
2/11/2017OppenheimerSet Price TargetBuy$200.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/10/2017CowenReiterated RatingOutperform$225.00N/A
i
2/10/2017Robert W. BairdReiterated RatingPositiveN/A
i
2/8/2017WedbushReiterated RatingOutperform$224.00N/A
i
1/27/2017WedbushReiterated RatingOutperform$224.00N/A
i
1/20/2017Needham & Company LLCDowngradeBuy ➝ HoldN/A
i
1/11/2017OppenheimerSet Price TargetBuy$200.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/30/2016WedbushReiterated RatingOutperform$224.00N/A
i
Rating by Liana Moussatos at Wedbush
12/16/2016WedbushReiterated RatingOutperform$224.00N/A
i
Rating by Liana Moussatos at Wedbush
11/26/2016WedbushReiterated RatingOutperform$224.00N/A
i
Rating by Liana Moussatos at Wedbush
11/18/2016Needham & Company LLCReiterated RatingBuy$350.00N/A
i
Rating by Alan Carr at Needham & Company LLC
11/18/2016FBR & CoReiterated RatingHold ➝ NeutralN/A
i
Rating by Vernon Bernardino at FBR & Co
11/15/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
11/11/2016WedbushReiterated RatingOutperform$224.00N/A
i
Rating by Liana Moussatos at Wedbush
11/7/2016Robert W. BairdReiterated RatingOutperform$332.00N/A
i
11/6/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Liisa Bayko at JMP Securities
11/3/2016WedbushReiterated RatingOutperform$224.00N/A
i
Rating by Liana Moussatos at Wedbush
11/3/2016Needham & Company LLCReiterated RatingBuy$350.00N/A
i
Rating by Alan Carr at Needham & Company LLC
11/2/2016CowenReiterated RatingBuy$225.00N/A
i
Rating by Ritu Baral at Cowen Inc
10/24/2016OppenheimerReiterated RatingOutperform$250.00 ➝ $200.00N/A
i
Rating by Carlos Solorzano at Oppenheimer Holdings Inc.
10/17/2016WedbushReiterated RatingOutperform$239.00N/A
i
Rating by Liana Moussatos at Wedbush
10/14/2016SVB LeerinkReiterated RatingPositive$159.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
10/7/2016WedbushReiterated RatingOutperform$239.00N/A
i
Rating by Liana Moussatos at Wedbush
9/28/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
9/25/2016WedbushReiterated RatingOutperform$239.00N/A
i
Rating by Liana Moussatos at Wedbush
9/22/2016Robert W. BairdReiterated RatingOutperform$332.00N/A
i
Rating by Brian Skorney at Robert W. Baird
9/22/2016Credit Suisse GroupReiterated RatingBuyN/A
i
Rating by Alethia Young at Credit Suisse Group AG
9/20/2016UBS GroupSet Price TargetBuy$180.00N/A
i
Rating by jeffrey hung at UBS Group AG
9/16/2016WedbushReiterated RatingOutperform$239.00N/A
i
Rating by Liana Moussatos at Wedbush
8/22/2016WedbushReiterated RatingOutperform$239.00N/A
i
Rating by Liana Moussatos at Wedbush
8/18/2016JMP SecuritiesReiterated RatingBuyN/A
i
Rating by Liisa Bayko at JMP Securities
8/18/2016FBR & CoReiterated RatingMarket Perform$200.00N/A
i
Rating by Vernon Bernardino at FBR & Co
8/12/2016WedbushReiterated RatingOutperform$239.00N/A
i
Rating by Liana Moussatos at Wedbush
8/8/2016Cantor FitzgeraldReiterated RatingSell$60.00N/A
i
8/5/2016Morgan StanleyReiterated RatingSell$80.00N/A
i
Rating by Andrew Berens at Morgan Stanley
8/5/2016BMO Capital MarketsReiterated RatingOutperform$219.00 ➝ $218.00N/A
i
Rating by Ian Somaiya at BMO Capital Markets
8/5/2016OppenheimerLower Price TargetOutperform$265.00 ➝ $250.00N/A
i
Rating by Carlos Solorzano at Oppenheimer Holdings Inc.
8/5/2016Credit Suisse GroupReiterated RatingBuy$200.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
8/5/2016LaidlawDowngradeBuy ➝ Sell$345.00 ➝ $105.00N/A
i
8/4/2016WedbushReiterated RatingOutperform$239.00N/A
i
Rating by Liana Moussatos at Wedbush
7/25/2016WedbushReiterated RatingOutperform$239.00N/A
i
Rating by Liana Moussatos at Wedbush
7/9/2016WedbushReiterated RatingBuy$239.00N/A
i
Rating by Liana Moussatos at Wedbush
7/6/2016Cantor FitzgeraldInitiated CoverageSell$58.00N/A
i
6/24/2016WedbushReiterated RatingOutperform$239.00N/A
i
Rating by Liana Moussatos at Wedbush
6/15/2016Robert W. BairdReiterated RatingOutperform$332.00N/A
i
Rating by Brian Skorney at Robert W. Baird
6/9/2016Robert W. BairdReiterated RatingOutperform$332.00N/A
i
Rating by Brian Skorney at Robert W. Baird
6/1/2016Robert W. BairdReiterated RatingOutperform$332.00N/A
i
Rating by Brian Skorney at Robert W. Baird
6/1/2016Needham & Company LLCReiterated RatingBuy$350.00N/A
i
Rating by Alan Carr at Needham & Company LLC
6/1/2016OppenheimerReiterated RatingBuyN/A
i
Rating by Carlos Solorzano at Oppenheimer Holdings Inc.
6/1/2016BarclaysReiterated RatingBuy$200.00 ➝ $205.00N/A
i
Rating by Jonathan Eckard at Barclays PLC
5/31/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
5/31/2016FBR & CoReiterated RatingHold$192.00 ➝ $200.00N/A
i
Rating by Vernon Bernardino at FBR & Co
5/31/2016SVB LeerinkReiterated RatingHold$144.00 ➝ $140.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
5/31/2016BMO Capital MarketsReiterated RatingBuy$221.00 ➝ $219.00N/A
i
Rating by Ian Somaiya at BMO Capital Markets
5/31/2016WedbushReiterated RatingOutperform$423.00 ➝ $239.00N/A
i
Rating by Liana Moussatos at Wedbush
5/31/2016Credit Suisse GroupReiterated RatingBuy$200.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
5/31/2016Morgan StanleyReiterated RatingUnderweight$80.00N/A
i
Rating by Andrew Berens at Morgan Stanley
5/31/2016JMP SecuritiesReiterated RatingMarket Outperform$200.00N/A
i
5/31/2016CowenBoost Price TargetOutperform$212.00 ➝ $215.00N/A
i
Rating by Ritu Baral at Cowen Inc
5/31/2016The Goldman Sachs GroupBoost Price TargetNeutral$114.00 ➝ $128.00N/A
i
Rating by Salveen Richter at The Goldman Sachs Group, Inc.
5/20/2016Needham & Company LLCReiterated RatingBuy$350.00N/A
i
Rating by Alan Carr at Needham & Company LLC
5/10/2016OppenheimerReiterated RatingBuyN/A
i
Rating by Carlos Solorzano at Oppenheimer Holdings Inc.
5/10/2016Credit Suisse GroupReiterated RatingBuy$200.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
5/9/2016FBR & CoUpgradeMarketperform ➝ OutperformN/A
i
Rating by Vernon Bernardino at FBR & Co
5/8/2016Morgan StanleyReiterated RatingSellN/A
i
Rating by Andrew Berens at Morgan Stanley
5/8/2016Robert W. BairdReiterated RatingBuyN/A
i
Rating by Brian Skorney at Robert W. Baird
5/6/2016WedbushReiterated RatingOutperformN/A
i
Rating by Liana Moussatos at Wedbush
5/6/2016CowenReiterated RatingBuy$212.00N/A
i
Rating by Ritu Baral at Cowen Inc
5/3/2016BMO Capital MarketsReiterated RatingBuy$239.00N/A
i
Rating by Ian Somaiya at BMO Capital Markets
5/3/2016Wells Fargo & CompanyReiterated RatingBuyN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
4/17/2016FBR & CoReiterated RatingHoldN/A
i
Rating by Vernon Bernardino at FBR & Co
4/17/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
4/12/2016BMO Capital MarketsReiterated RatingOutperform$239.00N/A
i
4/9/2016CowenReiterated RatingBuy$212.00N/A
i
Rating by Ritu Baral at Cowen Inc
4/9/2016Morgan StanleyReiterated RatingEqual ➝ SellN/A
i
Rating by Andrew Berens at Morgan Stanley
4/9/2016Bank of AmericaReiterated RatingSell$144.00N/A
i
Rating by Ying Huang at Bank of America Co.
4/9/2016Needham & Company LLCReiterated RatingBuy$350.00N/A
i
Rating by Alan Carr at Needham & Company LLC
4/9/2016OppenheimerReiterated RatingBuy$309.00N/A
i
Rating by Carlos Solorzano at Oppenheimer Holdings Inc.
4/8/2016Morgan StanleyDowngradeEqual Weight ➝ Underperform$100.00 ➝ $80.00N/A
i
Rating by Andrew Berens at Morgan Stanley
4/7/2016WedbushReiterated RatingOutperform$423.00N/A
i
Rating by Liana Moussatos at Wedbush
4/7/2016Credit Suisse GroupReiterated RatingBuy$200.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
4/6/2016BMO Capital MarketsInitiated CoverageOutperformN/A
i
4/6/2016SVB LeerinkReiterated RatingHold$144.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
4/5/2016FBR & CoReiterated RatingHold$192.00N/A
i
Rating by Vernon Bernardino at FBR & Co
4/5/2016Robert W. BairdReiterated RatingBuy$32.00N/A
i
Rating by Brian Skorney at Robert W. Baird
4/5/2016Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
4/1/2016Wells Fargo & CompanyReiterated RatingHold$171.00N/A
i
4/1/2016Morgan StanleyReiterated RatingEqual Weight$100.00N/A
i
Rating by Andrew Berens at Morgan Stanley
3/30/2016WedbushReiterated RatingOutperformN/A
i
Rating by Liana Moussatos at Wedbush
3/30/2016JMP SecuritiesReiterated RatingBuy$200.00N/A
i
3/30/2016The Goldman Sachs GroupInitiated CoverageBuy ➝ Neutral$114.00N/A
i
3/30/2016Credit Suisse GroupInitiated CoverageOutperform$200.00N/A
i
3/28/2016CowenReiterated RatingBuy$212.00N/A
i
Rating by Ritu Baral at Cowen Inc
3/23/2016SVB LeerinkReiterated RatingMarket PerformN/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
3/8/2016CowenReiterated RatingOutperform$212.00N/A
i
Rating by Ritu Baral at Cowen Inc
2/26/2016OppenheimerLower Price TargetOutperform$309.00N/A
i
Rating by Akiva Felt at Oppenheimer Holdings Inc.
2/26/2016CowenLower Price TargetOutperform$212.00N/A
i
Rating by Ritu Baral at Cowen Inc
2/24/2016BarclaysLower Price TargetOverweight$300.00 ➝ $200.00N/A
i
2/23/2016WedbushReiterated RatingOutperform$493.00 ➝ $423.00N/A
i
Rating by Liana Moussatos at Wedbush
1/29/2016Morgan StanleyUpgradeUnderweight ➝ Equal Weight$100.00N/A
i
Rating by Andrew Berens at Morgan Stanley
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 ➝ $111.91N/A
i
1/27/2016Needham & Company LLCReiterated RatingBuy$500.00N/A
i
Rating by Alan Carr at Needham & Company LLC
1/4/2016WedbushReiterated RatingOutperform$493.00N/A
i
Rating by Liana Moussatos at Wedbush
12/27/2015Needham & Company LLCReiterated RatingBuyN/A
i
Rating by Alan Carr at Needham & Company LLC
12/21/2015Needham & Company LLCReiterated RatingBuyN/A
i
Rating by Alan Carr at Needham & Company LLC
12/21/2015SVB LeerinkReiterated RatingHold$214.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
12/18/2015Robert W. BairdReiterated RatingBuy$346.00N/A
i
Rating by Brian Skorney at Robert W. Baird
12/18/2015JMP SecuritiesLower Price TargetMarket Outperform$348.00N/A
i
12/17/2015FBR & CoReiterated RatingMarket Perform$192.00N/A
i
Rating by Vernon Bernardino at FBR & Co
12/3/2015Needham & Company LLCReiterated RatingBuy$500.00N/A
i
Rating by Alan Carr at Needham & Company LLC
12/3/2015Wells Fargo & CompanyInitiated CoverageMarket PerformN/A
i
12/2/2015SVB LeerinkReiterated RatingHold$220.00 ➝ $214.00N/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
12/2/2015UBS GroupReiterated RatingBuyN/A
i
Rating by Matt Roden at UBS Group AG
12/2/2015WedbushReiterated RatingOutperform$493.00N/A
i
Rating by Liana Moussatos at Wedbush
(Data available from 11/24/2015 forward)
Intercept Pharmaceuticals logo
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More

Today's Range

Now: $36.42
$35.52
$37.59

50 Day Range

MA: $33.73
$27.79
$42.47

52 Week Range

Now: $36.42
$27.02
$125.00

Volume

13,806 shs

Average Volume

776,346 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84